MedPath

AYBINTIO

AYBINTIO

Approved
DIN Number

02522829

Drug Class

Human

Market Date

Jun 27, 2022

Company
HC

Samsung Bioepis Co., Ltd.

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02522829
AIG Number0151381001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription Recommended ,  Schedule D
A
ATC Code
L01FG01 BEVACIZUMAB
Product Specifications
Dosage FormSolution
Route of AdministrationIntravenous
AHFS Classification10:00.00
Health Canada Classification

ACTIVE INGREDIENTS (1)

BEVACIZUMABActive
Strength: 100 MG / 4 ML
Monograph: BEVACIZUMAB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.